A tumultuous 2026 is predicted for the U.S. healthcare industry as rising public discontent over costs sparks a period of significant revolution. Key shifts include the mainstreaming of wellness movements and the evolution of AI from experimental hype toward integrated growth engines, though implementation challenges remain. Meanwhile, pharmaceutical companies face intense scrutiny over drug pricing and PBM transparency while simultaneously navigating a more complex global regulatory landscape. Responsory’s takeaway: Leaders who understand the intersection of consumer anger, technological disruption, and regulatory pressure will be positioned to navigate consolidation, protect market position, and potentially emerge as “quiet heroes.”

View article